IL-36Ra (monomer):Fc (silent) InVivoKine™

After reconstitution: 1mg/ml

IL-36Ra/IL-1F5 is a highly and a specific antagonist of the IL-1 receptor-related protein 2-mediated response to IL-36alpha (IL-1F6), IL-36beta (IL-1F8) and IL-36gamma (IL-1F9). These cytokines bind to IL-36R (IL-1Rrp2) and IL-1RAcP, activating similar intracellular signals as IL-1. IL-36Ra inhibits the production of proinflammatory cytokines, including IL-12, IL-1beta, IL-6, TNF-alpha and IL-23 induced by IL-36 in BMDC and CD4 T cells. Skin and dendritic cells are target of the IL-36 interleukins leading to a Th1 response. Recently, mutations that affect the levels and the activity of IL-36Ra have been found in patients with pustular psoriasis, leading to enhanced production of inflammatory cytokines (IL-8 in particular) by keratinocytes. The IL-36Ra (mouse):Fc (silent) InVivoKine™ is produced by using two different vectors, one encoding for the IL-36Ra (mouse):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 52 kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein IL-36Ra (mouse) (monomeric):Fc (silent) InVivoKine™. The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

32160000

<0.01 EU/ug protein (LAL test).

solid

Lyophilized. Contains PBS.

After reconstitution, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. PBS containing at least 0. 1% BSA should be used for further dilutions.

InVivoKines™. Recombinant Protein. Mouse IL-36Ra (aa 3-156) is fused at the C-terminus to the Fc portions of human IgG1 (LALA-PG) (Knobs-into-Holes technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)). Produced in HEK 293 cells. Produced using animal component-free medium. IL-36Ra/IL-1F5 is a highly and a specific antagonist of the IL-1 receptor-related protein 2-mediated response to IL-36alpha (IL-1F6), IL-36beta (IL-1F8) and IL-36gamma (IL-1F9). These cytokines bind to IL-36R (IL-1Rrp2) and IL-1RAcP, activating similar intracellular signals as IL-1. IL-36Ra inhibits the production of proinflammatory cytokines, including IL-12, IL-1beta, IL-6, TNF-alpha and IL-23 induced by IL-36 in BMDC and CD4 T cells. Skin and dendritic cells are target of the IL-36 interleukins leading to a Th1 response. Recently, mutations that affect the levels and the activity of IL-36Ra have been found in patients with pustular psoriasis, leading to enhanced production of inflammatory cytokines (IL-8 in particular) by keratinocytes. The IL-36Ra (mouse):Fc (silent) InVivoKine™ is produced by using two different vectors, one encoding for the IL-36Ra (mouse):Fc (LALA-PG) Knobs sequence (synthesizing a protein of 52 kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein IL-36Ra (mouse) (monomeric):Fc (silent) InVivoKine™. The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

~ 52 kDa and ~ 28kDa (SDS-PAGE)

Q9QYY1

Plastic Vial

>95% (SDS-PAGE)

Mouse IL-36Ra (aa 3-156) is fused at the C-terminus to the Fc portions of human IgG1 (LALA-PG) (Knobs-into-Holes technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)).

Fc

Non-hazardous

Interleukins

41116127

Stable for at least 6 months after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.